Actu
TriCipher Joins SAFE BioPharma Association Vendor Partner Program
October 2007 by Marc Jacob
TriCipher today joined the SAFE (Signatures and Authentication for Everyone) BioPharma Association
Vendor Partner Program, pledging to promote the adoption of the SAFE
standards through the company’s user and transaction authentication
solutions. SAFE-approved credentials will seamlessly operate on
TriCipher Armored Credential System (TACS), the company’s strong
authentication platform leveraging a variety of multi-factor
credentials.
The industry group gives TriCipher access to forward-thinking corporate
users of digital information processing, such as Amgen, AstraZeneca,
Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson,
Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. By agreeing
to credentialing standards, these companies reduce the cost and time for
pharmaceutical companies to advance drug development and deploy new
business processes.
SAFE provides the industry’s legal foundation for digital signatures and
user authentication across pharmaceutical companies. Its standards are
legally enforceable because they ensure user authentication, digital
document integrity and auditable non-repudiation of users’ actions.
